Monoclonal antibodies (mAbs) selectively targeting TRAILshort have been shown to enhance cancer susceptibility to TRAIL and improve the efficacy of autologous CD8+ T cells in isolated primary tumors [11]. The gene discussed is CD8A; the disease is cancer.